Table_4_v1_Callispheres drug-eluting bead transhepatic artery chemoembolization with oral delivery of sorafenib for the treatment of unresectable liver cancer.docx

ObjectiveLiver cancer is a significant contributor to global burden of cancer. Transcatheter arterial chemoembolization (TACE) is the standard of care for patients with unresectable liver cancer, and CalliSpheres, as novel drug-eluting bead (DEB) microspheres, have been found to be associated with a high tumor response rate. However, the outcomes after DEB-TACE treatment are not always satisfactory with tumor recurrence. Herein, we attempt to compare the clinical efficacy and safety of DEB-TACE with sorafenib and conventional TACE in treating advanced liver cancer.MethodsThe study retrospectively reviewed clinical records of 96 patients with liver cancer, among which there were 48 cases receiving DEB-TACE with sorafenib and 48 cases receiving conventional TACE. The physical properties of Callispheres were evaluated in HepG2 cells and a B6/J mouse model.ResultsDEB-TACE with Callispheres were demonstrated to effectively maintain stability and prolong the half-life of epirubicin. Compared with the patients receiving conventional TACE, those receiving DEB-TACE with sorafenib exhibited better patient outcomes with increased survival rate, reduced tumor volume, and declined levels of tumor markers. Additionally, DEB-TACE with Callispheres could effectively protect liver function, as well as reduce the toxic effects of loaded epirubicin, and its combination with sorafenib would not increase the incidence of adverse reactions.ConclusionDEB-TACE using CalliSpheres combined with sorafenib could prevent the progression of liver cancer and bring a better prognosis.

肝脏癌作为一种对全球癌症负担产生重大影响的疾病，其治疗一直是医学研究的热点。经皮动脉化疗栓塞术（TACE）是治疗不可切除性肝脏癌的标准治疗方案。CalliSpheres作为一种新型的药物缓释微球，已被证实与较高的肿瘤反应率相关。然而，DEB-TACE治疗后的预后并不总是令人满意，肿瘤复发率较高。本研究旨在比较DEB-TACE联合索拉非尼与常规TACE在治疗晚期肝癌中的临床疗效与安全性。方法：本研究回顾性分析了96例肝癌患者的临床资料，其中48例接受DEB-TACE联合索拉非尼治疗，48例接受常规TACE治疗。在HepG2细胞和B6/J小鼠模型中评估了CalliSpheres的物理特性。结果：DEB-TACE联合CalliSpheres在维持稳定性及延长阿霉素半衰期方面显示出有效性。与接受常规TACE治疗的患者相比，接受DEB-TACE联合索拉非尼治疗的患者显示出更好的预后，包括生存率提高、肿瘤体积减小和肿瘤标志物水平下降。此外，DEB-TACE联合CalliSpheres可有效保护肝脏功能，降低载药阿霉素的毒性作用，且其与索拉非尼的联合使用不会增加不良反应的发生率。结论：使用CalliSpheres并结合索拉非尼的DEB-TACE治疗可防止肝癌的进展，并带来更佳的预后。